News & Updates

Follow the HUNTER Trial journey: protocol milestones, scientific insights, partnership announcements, and the latest developments in diabetes remission research.

Home / News
Featured Article
Announcements

Protocol Complete and Registration Pending—Seeking Clinical Partners Worldwide

December 5, 2025 HUNTER Research Team 5 min read

After 12 months of intensive development, the HUNTER Trial (HSE-T2D-001) protocol is complete and undergoing final ClinicalTrials.gov registration. We have finalized a 120-page, IRB-ready clinical trial protocol, mapped the FDA botanical drug pathway, identified GMP manufacturing partners, and developed comprehensive safety monitoring frameworks. We are now actively seeking Principal Investigators, clinical trial sites in Africa and globally, and funding partners committed to advancing affordable, evidence-based diabetes interventions.

Read Full Article
Research Insights

The Science Behind Hunteria umbellata: From Traditional Use to Clinical Trial

November 28, 2025 8 min read

For centuries, West African traditional healers have used Hunteria umbellata seeds to manage symptoms of what we now recognize as type 2 diabetes. But what does modern science tell us about this botanical? In this deep dive, we explore the ethnobotanical heritage, phytochemical composition, preclinical evidence, and unique alpha-glucosidase inhibition mechanism...

Read More
Partnerships

Why We're Pursuing an Africa-First Development Pathway

November 15, 2025 6 min read

Most botanical drugs discovered in Africa end up developed and commercialized in the Global North, with limited benefit to source communities. The HUNTER Trial takes a different approach. We're committed to Africa-first clinical development, ethical benefit-sharing under the Nagoya Protocol, and pricing structures that prioritize accessibility for low- and middle-income countries...

Read More
Announcements

Announcing Our Scientific Advisory Board Formation

Coming Soon TBD

We're thrilled to announce the formation of our Scientific Advisory Board, comprising independent experts in endocrinology, clinical pharmacology, botanical drug development, and biostatistics. These advisors will provide scientific oversight, protocol review, and data safety monitoring throughout the HUNTER Trial. Stay tuned for formal announcements...

Coming Soon
Research Insights

Understanding the Early Diabetes Remission Window: Why 12-24 Months Matters

Coming Soon TBD

Type 2 diabetes isn't a one-way street—at least not in the first 12-24 months after diagnosis. Landmark trials like DiRECT have shown that up to 77% of newly diagnosed patients can achieve remission with intensive lifestyle intervention. But what makes this early window so special? We break down the biology, the clinical evidence, and why HSE-01 targets this critical period...

Coming Soon